Astellas Sets Up Indian Subsidiary To Market Branded Drugs
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has established Astellas Pharma India in Mumbai with a stake of about $3.1 million. The Indian subsidiary is intended to boost Astellas' presence in emerging markets, with a particular emphasis on immunology and urology products. Astellas India plans to release its first immunosuppressant, Prograf (tacrolimus), in the next fiscal year, followed by alpha-1 blocker Harnal for prostates and Vesicare (solifenacin) for bladder problems. The new company does not intend to sell generics of other drugs. (Click here for more - a subscription may be required